China's Health Authority Proposes New Regulations on Gene Editing
Friday, March 1, 2019
China’s Health Authority Proposes New Regulations on Gene Editing
Following the controversial news of a Chinese scientist claiming that he produced two genetically edited baby girls, the Chinese government has proposed 16 pages of draft regulations that would require clinical trials involving gene-editing technologies to be classified as high- or low-risk, and to obtain approval from government authorities before proceeding with the work.
These regulations cover work involving gene editing, the transfer of genes or attempts to regulate gene expression, the use of stem cells, as well as high-risk technologies in humans or in organs and embryos to be implanted in a person.
As previously stated, ISCT endorses the statement issued by NIH Director Francis Collins. In light of the early stages of our understanding of the consequences of gene editing, ISCT supports the development of an international consensus on setting limits for human germline editing.
The draft regulations (available in Chinese only) are posted on the National Health Commission website and open for comment until March 27, 2019. http://www.nhfpc.gov.cn/yzygj/s7659/201902/0f24ddc242c24212abc42aa8b539584d.shtml